Important Prescribing Information
Palbociclib is an oral targeted anticancer medicine classified as a CDK4/6 inhibitor.
It is used in combination with appropriate endocrine therapy for specified patients with advanced or metastatic breast cancer.
This page summarizes important prescribing considerations for palbociclib. It is not a substitute for the complete, current prescribing information for the specific product and country.
Palboxen is identified as a 125 mg palbociclib product in the supplied product information. The precise formulation and approved product labeling must be verified before applying reference-product instructions to Palboxen.
Active Ingredient
Generic name: Palbociclib
Stated product strength: 125 mg
Pharmacological class: Cyclin-dependent kinase 4 and 6 inhibitor.
Therapeutic category: Antineoplastic medicine.
Palbociclib inhibits CDK4 and CDK6, interfering with cell-cycle progression in susceptible cancer cells.
Therapeutic Indications
Palbociclib is used in specified breast cancer treatment settings, particularly hormone receptor-positive and HER2-negative advanced or metastatic breast cancer.
Depending on the applicable regulatory authorization, treatment combinations may include:
- An aromatase inhibitor.
- Fulvestrant.
- Appropriate ovarian suppression in premenopausal or perimenopausal women receiving endocrine therapy.
The exact indication depends on the patient’s treatment setting and the applicable local product authorization.
Newer regulatory indications and combinations may differ by jurisdiction and reference-label version. Healthcare professionals should consult the current approved label in their country.
Dosage and Administration
A commonly used reference starting dose is:
125 mg orally once daily for 21 consecutive days, followed by 7 days without palbociclib.
This is a 28-day treatment cycle.
| Treatment component | Reference regimen |
|---|---|
| Starting dose | 125 mg once daily |
| Treatment duration | 21 consecutive days |
| Treatment break | 7 days |
| Cycle length | 28 days |
| First common dose reduction | 100 mg once daily |
| Second common dose reduction | 75 mg once daily |
The prescribed dose may need adjustment depending on adverse reactions, blood-count results, drug interactions and other clinical considerations.
Administration Instructions
Palbociclib is taken orally in its reference formulations.
Administration instructions differ by dosage form.
Capsules: Reference capsules should be taken with food. They should be swallowed whole and should not be chewed, crushed or opened. Damaged or broken capsules should not be used.
Tablets: Reference tablets may be taken with or without food. They should be swallowed according to the official product instructions and should not be crushed, chewed or divided unless specifically permitted.
The exact dosage form of Palboxen must be verified before applying either set of instructions.
Missed or Vomited Dose
If a patient misses a dose, an additional dose should not be taken to compensate.
If vomiting occurs after administration, the patient should not automatically take another dose.
The next dose should be taken at the regularly scheduled time according to the applicable product instructions.
Patients should contact their healthcare professional if they are uncertain about what to do.
Dose Modification
Dose interruption or reduction may be necessary when adverse reactions occur.
Common reference dose levels are:
- 125 mg once daily.
- 100 mg once daily.
- 75 mg once daily.
Neutropenia is a major reason for treatment interruption or dose reduction.
The oncology team should review the complete blood count and assess the clinical condition before restarting or changing treatment.
Further dose modification or discontinuation may be necessary when adverse reactions are severe, recurrent or clinically significant.
Contraindications and Patient Assessment
Contraindications and restrictions should be checked against the specific product’s approved prescribing information.
The absence of a listed formal contraindication does not mean palbociclib is suitable for every patient.
Before treatment, the healthcare professional should review:
- Known allergies to the active ingredient or product components.
- Pregnancy status and reproductive considerations.
- Previous infections.
- Liver disease.
- Lung disease.
- Blood-count abnormalities.
- Current medicines and supplements.
- Previous anticancer treatments.
- Other significant medical conditions.
Important Warnings
Neutropenia
Neutropenia is a major adverse reaction associated with palbociclib.
A reduction in neutrophils can increase the risk of infection. Complete blood counts should be monitored according to the applicable prescribing information.
Patients should promptly report fever or other symptoms suggesting infection.
Interstitial Lung Disease and Pneumonitis
Rare cases of interstitial lung disease or pneumonitis have been reported with CDK4/6 inhibitors, including palbociclib.
New or worsening respiratory symptoms should be evaluated promptly.
Severe cases may require treatment interruption or permanent discontinuation according to the applicable product labeling.
Embryo-Fetal Toxicity
Palbociclib may cause fetal harm.
Patients who can become pregnant should discuss pregnancy prevention and the required precautions with their healthcare professional.
Pregnancy-related warnings and contraception instructions should follow the current official prescribing information.
Liver Function
Liver-related abnormalities may occur during treatment.
Healthcare professionals should assess liver function when clinically appropriate and investigate symptoms suggesting possible hepatic injury.
Drug Interactions
Palbociclib is metabolized mainly by CYP3A.
Strong CYP3A inhibitors: These can increase palbociclib exposure and may increase adverse effects. Avoidance or specialist-directed dose adjustment may be required.
Strong CYP3A inducers: These can decrease palbociclib exposure and may reduce treatment effectiveness. Their use should generally be avoided according to the applicable prescribing information.
CYP3A substrates: Palbociclib may affect exposure to certain medicines metabolized through CYP3A. Sensitive substrates with a narrow therapeutic index require particular attention.
A full medication review should be performed before treatment and whenever a new medicine is started.
Laboratory Monitoring
Complete blood count monitoring is an essential part of palbociclib treatment.
Reference prescribing information recommends:
- A complete blood count before starting treatment.
- A complete blood count at the beginning of each cycle.
- A complete blood count on Day 15 of the first two cycles.
- Additional testing when clinically indicated.
Blood tests help identify neutropenia and other blood-cell abnormalities that may require treatment modification.
Other investigations, including liver-function tests, may be requested depending on the patient’s clinical condition.
Adverse Reactions
Commonly reported adverse reactions include:
- Neutropenia.
- Leukopenia.
- Anemia.
- Thrombocytopenia.
- Fatigue.
- Nausea.
- Diarrhea.
- Stomatitis.
- Reduced appetite.
- Infections.
- Hair thinning.
- Abnormal liver-function test results.
Serious adverse reactions may include severe infections and rare pulmonary complications.
Patients should receive clear instructions about symptoms that require urgent medical assessment.
Pregnancy and Lactation
Palbociclib may cause fetal harm.
Patients who are pregnant or planning pregnancy should discuss treatment risks and alternatives with their healthcare professional.
Breastfeeding should be avoided during treatment and for the period specified in the applicable official prescribing information after the final dose.
Storage and Handling
Storage conditions must be taken from the specific product’s approved labeling.
Patients should:
- Keep the medicine in its original packaging where appropriate.
- Follow the labeled temperature conditions.
- Keep it out of children’s reach.
- Avoid using expired medicine.
- Avoid using damaged or unidentified products.
- Ask a pharmacist about proper handling and disposal.
Prescribing Information Disclaimer
This page provides a general summary of palbociclib prescribing considerations. It is not the complete official prescribing information for Palboxen.
Healthcare professionals must consult the current approved labeling applicable to the exact product, formulation and country before prescribing or dispensing the medicine.